Hara T, Nishikawa S, Miyazaki H, Ohguro Y
Jpn J Antibiot. 1983 Jan;36(1):177-81.
Micronomicin (MCR) is a new aminoglycoside antibiotic produced by Micromonospora sagamiensis var. nonreducans which was isolated from soil collected at Sagamihara by Nara et al. The purified antibiotic showed a close similarity to gentamicin C complex in physical and chemical properties. The antibacterial activity of MCR is broad-spectrum and almost equal to that of gentamicin C complex. MCR exhibits particularly high activity against Pseudomonas, Proteus, Klebsiella pneumoniae, Serratia, etc. and high activity against some Pseudomonas aeruginosa strains resistant to gentamicin C1a. Teratogenicity studies of MCR in rats were carried out by intravenous injection for safety evaluation (Dose; 25, 50 mg/kg and 75 mg/kg). The results of studies are as follows. 1. Fetal malformation attributable to MCR was not observed at any dose. 2. Suppression of maternal weight gain was observed at the dose levels of 50 mg/kg and over. 3. There was no adverse effect on new borns at any dose.
小诺米星（MCR）是由相模小单孢菌非还原变种产生的一种新型氨基糖苷类抗生素，该菌株由奈良等人从相模原采集的土壤中分离得到。纯化后的抗生素在物理和化学性质上与庆大霉素C复合物极为相似。MCR的抗菌活性具有广谱性，几乎与庆大霉素C复合物相当。MCR对假单胞菌属、变形杆菌属、肺炎克雷伯菌、沙雷氏菌属等具有特别高的活性，对一些耐庆大霉素C1a的铜绿假单胞菌菌株也具有高活性。通过静脉注射进行了MCR对大鼠的致畸性研究以进行安全性评估（剂量：25、50毫克/千克和75毫克/千克）。研究结果如下：1. 任何剂量下均未观察到由MCR导致的胎儿畸形。2. 在50毫克/千克及以上剂量水平观察到母体体重增加受到抑制。3. 任何剂量下对新生儿均无不良影响。
